The study seeks to define the expected blood levels of pre-exposure prophylaxis (PrEP)
medications (tenofovir) for cisgender women taking directly observed oral PrEP therapy to
understand the frequency of PrEP dosing associated with HIV protection in cisgender women.
Cisgender women will be randomly assigned to receive varying frequency of weekly PrEP doses
and followed for up to 16 weeks. The study will also investigate how pregnancy affects the
expected blood levels to help define optimal dosing of PrEP for HIV prevention during
pregnancy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Washington
Collaborators:
Kenya Medical Research Institute National Institute of Allergy and Infectious Diseases (NIAID) University of Colorado, Denver
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination